Latest News & Features
Americas
The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers. 18 March 2021
article
The Patent Trial and Appeal Board is an important forum for determining a US patent’s validity. Since 2012, when inter partes review of US patents began, the PTAB’s cancellation rate for challenged patents has varied dramatically. 18 March 2021
Big Pharma
The National Collegiate Athletic Association has filed a petition to cancel a urology centre's ‘Vasectomy Mayhem’ trademark ahead of the NCAA’s March Madness Basketball Tournament. 16 March 2021
Big Pharma
Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed. 16 March 2021
Americas
Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled. 15 March 2021
Big Pharma
Ireland is the latest country to come under pressure to back the World Trade Organisation’s appeal to waive intellectual property rights related to COVID-19 vaccines, as developing countries struggle to vaccinate their populace. 12 March 2021
Medtech
The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents. 11 March 2021
Biotechnology
China must safeguard IP in the seed industry to ensure innovation within the sector, the group chairman of Chinese multinational Sinochem, Frank Ning, has warned. 11 March 2021
Big Pharma
Ferring Pharmaceuticals has asked The District Court for the Southern District of New York to impose sanctions on law firm Jones Day for allegedly forcing its client Serenity Pharmaceuticals into pursuing litigation against Ferring. 11 March 2021
article
As a follow-on from last week's Regeneron v Kymab webinar, where we looked at how and why the Supreme Court reversed the Court of Appeal and found Regeneron's patents for transgenic mouse technology invalid for insufficiency, we pick up the discussion to reflect on the broader impact of the ruling. 11 March 2021